Clinical Trials

Phase III Randomized Study of Ultraviolet A Light Therapy with Methoxsalen (PUVA) with or without Bexarotene in Patients with Mycosis Fungoides

United Kingdom

OBJECTIVE: Compare the cumulative dose of ultraviolet A light required to achieve a complete clinic response (CCR) and overall response rate (complete or partial) in patients with mycosis fungoides treated with ultraviolet A light therapy with PUVA with or without bexarotene.

ELIGIBILITY REQUIREMENTS: Histologically confirmed mycosis fungoides Stage IB or IIA. Age over 18. Not pregnant of nursing. Willing and able to avoid prolonged exposure to the sun. No prior intolerance of or unresponsiveness to PUVA therapy. No other concurrent serious illness or infection. No uncontrolled diabetes mellitus or uncontrolled thyroid disease.

EORTC Cutaneous Lymphoma Task Force
ST. John’s Institute of Dermatology
Sean Whittaker MD PH: 44-20-792-892-92 ext. 1333
London, United Kingdom

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.